SCHEDULE: Indaptus Therapeutics: Investors Disband Group, Ownership Shifts

Several significant shareholders in Indaptus Therapeutics have formally disbanded their reporting group, with one shareholder falling below the 5% ownership threshold.

Summary

• This filing is an amendment to a previous Schedule 13D, primarily to clarify that the reporting persons have disbanded their group and will no longer operate as a group.
• Lina Deng is no longer considered a beneficial owner of more than five percent of Indaptus Therapeutics' common stock due to an increase in the total number of outstanding shares.
• The filing confirms the ownership stakes of Yun Yao (37.1%), Sino Lion Ventures Ltd (34.3%), Xu Chenhao (34.3%), Dai Junyi (9.9%), and Ting Yang (9.9%).
• The total number of outstanding shares of common stock as of March 31, 2026, was 113,242,324.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, primarily an administrative update clarifying group status and ownership changes without new operational or financial information.

Positives

• Clarification of group disbandment provides transparency for investors.
• The company has a significant number of shares outstanding, indicating potential for broader investor base.

Negatives

• Lina Deng's stake has fallen below the 5% threshold, which could indicate a reduction in her investment or confidence.
• The disbandment of a group that previously held a significant combined stake might suggest a lack of coordinated strategy among these investors.

Risks

• The disbandment of a previously formed group could lead to less coordinated shareholder action, potentially impacting corporate governance or strategic decisions.
• A decrease in a significant shareholder's stake below the 5% threshold might signal a shift in their investment strategy or confidence in the company's future performance.

Future Outlook

The filing does not contain specific forward-looking statements or guidance. It primarily serves to update ownership information and clarify group status.

Industry Context

StockSavvy.ai notes that the disbandment of a shareholder group and shifts in beneficial ownership percentages are common events in the biotechnology and pharmaceutical sectors, often reflecting evolving investment strategies or portfolio adjustments among institutional and individual investors.

Stakeholder Impact

• Shareholders: Increased transparency regarding individual ownership stakes and the dissolution of a previously identified group.
• Management: May need to engage with individual large shareholders rather than a coordinated group.

Next Steps

• The filing is designated as a final amendment and an 'exit filing' for Lina Deng, suggesting no further immediate updates are anticipated from her regarding this specific filing.

Key Dates

Keywords

Indaptus Therapeutics, Schedule 13D, Ownership, Shareholder Group, Securities, SEC Filing, Common Stock, Beneficial Ownership